Skip to main content
BiomX Inc. logo

BiomX Inc. — Investor Relations & Filings

Ticker · PHGE ISIN · US09090D1037 US Manufacturing
Open in API
Filings indexed 514 across all filing types
Latest filing 2026-06-05 Transaction in Own Shar…
Country US United States of America
Listing US PHGE

About BiomX Inc.

https://www.biomx.com/

BiomX Inc. is a clinical-stage company developing phage therapies to target and destroy harmful bacteria. The company creates both natural and engineered phage cocktails and personalized treatments for chronic diseases. Its therapeutic pipeline focuses on conditions such as cystic fibrosis and diabetic foot osteomyelitis. BiomX's platform discovers and validates proprietary bacterial targets, allowing for the customization of phage compositions against these specific pathogens.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Transaction in Own Shares Classification · 88% confidence The document is a U.S. SEC Form 8-K “Current Report” disclosing Item 3.02 “Unregistered Sales of Equity Securities,” detailing the issuance of 1,013,637 shares upon conversion of a promissory note and attached exhibits for the credit line, note, and warrant. This is a report of the company issuing its own shares. According to the taxonomy, this falls under “Transaction in Own Shares” (POS).
2026-06-05 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Current Report on Form 8-K filed with the SEC, specifically Item 5.02 “Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.” It announces the appointment of a new Chief Business Officer and details his compensation and related arrangements. This is a management change announcement, fitting the definition of Board/Management Information (MANG).
2026-05-28 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2026
2026-05-20 English
10-K/A - BiomX Inc. (0001739174) (Filer)
Annual Report FY 2025
2026-04-30 English
8-K - BiomX Inc. (0001739174) (Filer)
Regulatory Filings
2026-04-16 English
8-K - BiomX Inc. (0001739174) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC by BiomX Inc. on April 13, 2026. It reports the entry into a material definitive agreement, specifically a Stock Purchase & Assignment Agreement to acquire a majority stake in DR. Frucht Systems Ltd. The document includes detailed descriptions of the transaction terms, securities issued, and related agreements. It also contains exhibits such as the convertible promissory note, warrants, and the stock purchase agreement. The filing is a current report on a significant corporate event, not a full annual or quarterly report, nor an earnings release or proxy statement. It is not a regulatory filing of miscellaneous nature but a specific event-driven report. Therefore, the appropriate classification is a Capital/Financing Update (CAP), as it relates to acquisition and issuance of securities as consideration.
2026-04-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.